Takaaki Ishii
Private Equity Investor bei Taiho Ventures LLC
Profil
Takaaki Ishii, a molecular biologist by training, joined Taiho Ventures in 2019.
He has acquired over 11 years of oncology expertise in early stage clinical development, product portfolio strategies as well as scientific evaluations for in-house and potential partnering programs in a wide range of cancer types.
His representative contribution to Taiho Pharmaceutical includes in-licensing AB928 (A2aR/A2bR Dual Antagonist) from Arcus Biosciences as well as both medical and Medical Science Liaison activities for nab-paclitaxel (ABRAXANE®) and pembrolizumab (KEYTRUDA®) in Japan.
Aktive Positionen von Takaaki Ishii
| Unternehmen | Position | Beginn |
|---|---|---|
Taiho Ventures LLC
 Taiho Ventures LLC Investment ManagersFinance Taiho Ventures LLC (Taiho Ventures) is a venture and private equity subsidiary of Taiho Pharmaceutical Co Ltd founded in 2016. The firm is headquartered in Menlo Park, California. | Private Equity Investor | 01.01.2019 |
Ausbildung von Takaaki Ishii
| Tokyo Institute of Technology | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Taiho Ventures LLC
Taiho Ventures LLC Investment ManagersFinance Taiho Ventures LLC (Taiho Ventures) is a venture and private equity subsidiary of Taiho Pharmaceutical Co Ltd founded in 2016. The firm is headquartered in Menlo Park, California. | Finance |
